Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-25T21:31:58.198Z Has data issue: false hasContentIssue false

Chapter 53 - HPV Immunization

from Section 11 - Public Health Issues in Gynaecology

Published online by Cambridge University Press:  24 November 2021

By
Antonios Athanasiou  and
Ilkka Kalliala
Edited by
Tahir Mahmood ,
Charles Savona-Ventura ,
Ioannis Messinis  and
Sambit Mukhopadhyay
Tahir Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Charles Savona-Ventura
Affiliation:
University of Malta, Malta
Ioannis Messinis
Affiliation:
University of Thessaly, Greece
Sambit Mukhopadhyay
Affiliation:
Norfolk & Norwich University Hospital, UK
Get access

Summary

Vaccines against HPV are highly efficacious in preventing infection and disease in the cervix, vulva, anus, oropharynx as well as the anogenital warts caused by HPV types included in the vaccine cocktail. The efficacy is optimal if vaccines are given in prepubertal girls and boys before coitarche, while it remains an individual choice for older women. Vaccination is efficacious in women who have been infected but cleared the infection, although the upper age of vaccination depends on cost-effectiveness and is country-specific. School-based gender-neutral vaccination optimizes coverage and herd immunity. Two doses suffice under the age of 15 with an interval of 6–12 months, while the standard three-dose regimen is recommended thereafter. Vaccine will modify screening strategies, possibly with longer screening intervals in vaccinated cohorts, but will not obviate them. Vaccination in low-resource setting is especially important as lack of infrastructure prevents screening, but affordability remains a major issue.

Keywords

HPVimmunizationcervical cancervaccineprevention
Type
Chapter
Information
The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology
Gynaecology
 , pp. 457 - 466
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lehtinen, M, Dillner, J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013;10:400–410.CrossRefGoogle ScholarPubMed
International Agency For Research On Cancer (IARC). Cancer today. 2018. Available from: http://gco.iarc.fr/today/home.Google Scholar
Hartwig, S, St Guily, JL, Dominiak-Felden, G, Alemany, L, de Sanjose, S. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agent Cancer 2017;12:19.Google Scholar
Joura, EA, Pils, S. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both? Clin Microbiol Infect 2016;22(Suppl 5):S125–SS27.Google Scholar
Pils, S, Joura, EA. From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect 2015;21:827–833.Google Scholar
Harder, T, Wichmann, O, Klug, SJ, et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med 2018;16:110.CrossRefGoogle ScholarPubMed
Munoz, N, Kjaer, SK, Sigurdsson, K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:325–339.Google Scholar
Arbyn, M, Xu, L, Simoens, C, Martin-Hirsch, PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;5:CD009069.Google Scholar
Joura, EA, Giuliano, AR, Iversen, OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711–723.CrossRefGoogle ScholarPubMed
van Rijn, VM, Mooij, SH, Mollers, M, et al. Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. PLoS One 2014;9:e92208.CrossRefGoogle ScholarPubMed
Luostarinen, T, Apter, D, Dillner, J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer 2018;142:2186–2187.CrossRefGoogle ScholarPubMed
Lehtinen, M, Paavonen, J, Wheeler, CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89–99.Google Scholar
Yoshikawa, H, Ebihara, K, Tanaka, Y, Noda, K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 2013;104:465–472.CrossRefGoogle ScholarPubMed
Drolet, M, Benard, E, Boily, MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565–580.Google Scholar
Kavanagh, K, Pollock, KG, Cuschieri, K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017;17:1293–1302.CrossRefGoogle Scholar
Mesher, D, Panwar, K, Thomas, SL, et al. The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific hPV in young females, 2010–2016. J Infect Dis 2018;218:911–921.Google Scholar
Lee, LY, Garland, SM. Human papillomavirus vaccination: the population impact. F1000Res 2017;6:866.CrossRefGoogle ScholarPubMed
Kyrgiou, M, Athanasiou, A, Paraskevaidi, M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016;354:i3633.Google Scholar
Guo, F, Cofie, LE, Berenson, AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med 2018;55:197–204.CrossRefGoogle ScholarPubMed
WHO-GACVS. Safety update of HPV vaccines. 2017. Available from: www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en.Google Scholar
Kjaer, SK, Nygard, M, Dillner, J, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis 2018:339–345.CrossRefGoogle Scholar
Castellsague, X, Munoz, N, Pitisuttithum, P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 2011;105:28–37.CrossRefGoogle ScholarPubMed
Olsson, SE, Kjaer, SK, Sigurdsson, K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009;5:696–704.Google Scholar
Joura, EA, Garland, SM, Paavonen, J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401.Google Scholar
Garland, SM, Paavonen, J, Jaisamrarn, U, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial. Int J Cancer 2016;139:2812–2826.Google Scholar
Ghelardi, A, Parazzini, F, Martella, F, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol 2018;151:229–234.CrossRefGoogle ScholarPubMed
Brisson, M, Benard, E, Drolet, M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016;1:e8–e17.CrossRefGoogle ScholarPubMed
Jit, M, Brisson, M, Portnoy, A, Hutubessi, R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2014;2:e406–e414.Google Scholar
Bosch, FX, Robles, C, Diaz, M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119–132.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×